Consistent with ABCG2, TOX3, or WDR5 itself also shows the abnormally high expression in the metastasized or recurrent CRC tissues after receiving chemotherapy, and their respective activation confers stem-like traits and drug insensitivity enhancement in CRC cells. This evidence concerns the gene TOX3 and colorectal carcinoma.